Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[MyD88 L265P mutation and B cell tumor].

Zhongguo shi yan xue ye xue za zhi - 1 Feb 2014

Chen Hai-Min, Hou Jian

Abstract excerpt

Myeloid differentiation factor (MyD88) is an important adaptor protein mediating the signal transduction of most Toll-like receptors (TLR), interleukin-1 receptor (IL-1R) and interleukin-18 receptor (IL-18R) that play a key role to mediate innate immune response. Recently, activating of MYD88 L265 mutation has been reported in about of 90% lymphoplasmacytoid lymphoma/Waldenström's Macroglobulinemia, about of 29%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to MYD88 gene
Share to Lymphoma, Large B-Cell, Diffuse
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinogenesis

Share to Myeloid Differentiation Factor 88

Share to Signal Transduction

Source

Identifiers

PMID: 24598687
DOI: 10.7534/j.issn.1009-2137.2014.01.048

Genes

MYD88

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[MyD88 L265P mutation and B cell tumor].PMID 24598687Read ↗

MYD88 <sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapySemantic proximity Read ↗

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.Semantic proximity Read ↗

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.Semantic proximity Read ↗

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.Semantic proximity Read ↗

[The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].Semantic proximity Read ↗

MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

Expression of MYD88 L265P Mutation in Subtypes of Diffuse Large B-Cell Lymphoma in the Pakistani Population.Semantic proximity Read ↗

Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.Semantic proximity Read ↗

Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.Semantic proximity Read ↗

A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival.Semantic proximity Read ↗

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.